News and Announcements
Walker Capital posts positive return for the month of February
- Published March 07, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Highlights
- February has produced a positive return for all strategies with an outstanding result in particular for the High Growth Strategy.
- Designed to perform in market volatility and difficult market conditions, the
- High Growth Strategy posted a 48.92% net return for February.
All other strategies posted positive net returns for the month of February.
February has produced a positive return for all strategies with an outstanding result in particular for the High Growth Strategy.
Designed to perform in market volatility and difficult market conditions, the High Growth Strategy posted a 48.92% net return for February.
Swing trading, based on fundamental and technical analysis using trends and Fibonacci levels posted a 2.2% net return for February.
The Multi Strategy, an algorithmic trading system on Forex and commodities which identifies price patterns for emerging and breakout opportunities posted a 0.88% net return for February.
The Growth strategy posted a 1.07% net return for February.
About Walker Capital
Walker Capital is to raise up to $900,000 for 20% in equity. The capital will be used to fund the expansion of the Company as it increases its marketing campaign aimed at expanding its client base and developing an investment platform for its clients.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
